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Alzheimer’s Disease (AD)-Like Pathology in Aged Monkeys
after Infantile Exposure to Environmental Metal Lead (Pb):
Evidence for a Developmental Origin and Environmental
Link for AD
JinfangWu,1Md. Riyaz Basha,1 Brian Brock,1David P. Cox,2 Fernando Cardozo-Pelaez,2 Christopher A. McPherson,3
Jean Harry,3Deborah C. Rice,4 BryanMaloney,5Demao Chen,5Debomoy K. Lahiri,5 and Nasser H. Zawia1
1Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island 02881, 2Department of Biomedical and
Pharmaceutical Sciences, Center for Environmental Health Sciences, University of Montana, Missoula, Montana 59812, 3National Institutes of Health,
Research Triangle Park, North Carolina 27709, 4Maine Department of Health and Human Services, Augusta, Maine 04333, and 5Laboratory for Molecular
Neurogenetics, Institute for Psychiatric Research, Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana 46202
The sporadic nature of Alzheimer’s disease (AD) argues for an environmental link that may drive AD pathogenesis; however, the
triggering factors and the period of their action are unknown. Recent studies in rodents have shown that exposure to lead (Pb) during
brain development predetermined the expression and regulation of the amyloid precursor protein (APP) and its amyloidogenic
-amyloid (A) product in old age.Here,we report that the expressionofAD-related genes [APP,BACE1 (-siteAPPcleaving enzyme1)]
as well as their transcriptional regulator (Sp1) were elevated in aged (23-year-old) monkeys exposed to Pb as infants. Furthermore,
developmental exposure to Pb altered the levels, characteristics, and intracellular distribution of A staining and amyloid plaques in the
frontal association cortex. These latent effects were accompanied by a decrease in DNA methyltransferase activity and higher levels of
oxidative damage toDNA, indicating that epigenetic imprinting in early life influenced the expression of AD-related genes and promoted
DNA damage and pathogenesis. These data suggest that AD pathogenesis is influenced by early life exposures and argue for both an
environmental trigger and a developmental origin of AD.
Key words: amyloidogenesis; development; environmental exposure; Pb; epigenetic regulation; transcription factor
Introduction
Alzheimer’s disease (AD) is a progressive and irreversible neuro-
degenerative disorder that results in dementia and death. AD
pathology is characterized by senile plaques and neurofibrillary
tangles (NFTs), combined with massive neuronal loss, mainly in
the hippocampus and association regions of the neocortex (Ball
and Lo, 1977). The major constituents of senile plaques are
39–43 aa peptides [-amyloid (A)], snipped from a larger pro-
tein called A precursor protein (APP) (Glenner and Wong,
1984; Masters et al., 1985; Goldgaber et al., 1987). Recent studies
indicate that APP is processed by a group of secretases
(Dominguez et al., 2004). The -secretase generates a soluble
product, whereas -secretase and -secretase generate A from
APP (Walsh et al., 2007).
The sporadic nature of most AD cases strongly argues for an
environmental link that may drive AD pathogenesis; however, it
is not clearwhen thismay occur. Reconstructions of neonatal and
medical histories of birth cohorts have led to the origin of the
“Barker hypothesis” (Barker et al., 1989; Osmond and Barker,
2000), which links early life experiences and adult diseases. These
observations resulted in a new concept regarding certain adult
diseases that emphasizes the role of environmental factors oper-
ating during the preconceptual, fetal, and infantile phases of life
(Gluckman and Hanson, 2004).
The pathological manifestations in AD patients are presumed
to result from defects of old age; however, it is unlikely that the
disease process begins late in life. Therefore, amyloidogenesis
associated with AD can also be viewed as a pathological outcome
that is evident during aging; however, the preceding initiating
event may have occurred during early stages of brain develop-
ment (Zawia andBasha, 2005). Specifically, this eventwould have
been a LEARn (latent early-life associated regulation) alteration
(Lahiri et al., 2007) affecting the expression of genes associated
with a later-manifest condition.
Previous work from our laboratories showed that develop-
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mental exposure of rats to the metal Pb from birth to postnatal
day 20 showed a delayed overexpression of APP and elevation of
its amyloidogenic A product in old age (Basha et al., 2005). We
also observed elevations in the oxidative DNA marker
8-hydroxy-2-deoxyguanosine (8-oxo-dG) in older rats that had
been developmentally exposed to Pb (Bolin et al., 2006). These
findings suggested that environmental influences occurring dur-
ing brain development predetermined the expression, regulation,
and processing of APP later in life, potentially influencing the
course of amyloidogenesis and oxidative damage.
To link these molecular and oxidative perturbations observed
in rats to pathological consequences associated with AD, we ex-
amined the brains of aged cynomolgus monkeys that were simi-
larly exposed to Pb as infants. Primates are among a few animal
models that express amyloid plaques and other pathological fea-
tures that are absent in wild-type/nontransgenic rodents. This
studywas undertaken to determinewhether nonhuman primates
that exhibit similar AD-like pathology in old age (Price and Siso-
dia, 1994) would be influenced by developmental perturbations,
and to explore the potential mechanisms that couldmediate such
latent effects.
Materials andMethods
Animal exposure. In 1980–1981, a cohort of female monkeys (Macaca
fascicularis) was randomly assigned at birth to one of two exposure
groups: one received 1.5 mg  kg1  d1 of lead acetate (Pb) from birth
until 400 d of age via infant formula and vehicle after weaning, whereas
the other group served as a control group and received formula or vehicle
only. No overt signs of toxicity or health-related problems were evident
in the animals as a result of Pb exposure (Rice, 1990, 1992). They were
then transferred to National Institutes of Health (NIH) facility until
termination in 2003 at23 years of age and all animal procedures were
conducted under the supervision of a licensed veterinarian according to
a National Institute on Environmental Health Sciences–NIH-approved
animal protocol. As previously reported, the blood lead levels of these
animals at 400 d of age averaged 19–26 g/dl in Pb-exposed monkeys
compared with 3–6 g/dl in the controls (Rice, 1990, 1992). The mon-
keys were terminated in 2003 (23 years later), andmultiple organ tissues,
including the brain, were collected, cut in 1 cm sections, and immediately
processed in 10% formalin for histopathology or frozen on dry ice and
stored at80°C. At this time, the animals were in good health, and there
were no indications of adverse health effects as a result of early Pb
exposure.
Total RNA isolation, synthesis of cDNA, and real-time PCR. RNA from
various control and exposedmonkey cortical tissues was isolated accord-
ing to the TRIzol method (Invitrogen, San Diego, CA). The RNA was
reverse transcribed to obtain cDNAs, catalyzed by SuperScript III Re-
verse Transcriptase (RT). The RNA/primermixture containing 500 ng of
total RNA, 1l of 10 mM dNTPmix, and 1l of oligo-dT was incubated
at 65°C for 5 min. A reaction mixture containing 2 l of 10 RT buffer
(200mMTris-HCl, pH8.4, 500mMKCl), 4l of 25mMMgCl2, 2l of 0.1
M DTT, and 1 l of RNaseOUT recombinant RNase inhibitor (40 U/l)
was added. One microliter of SuperScript III RT (200 U/l) was then
added and incubated at 50°C for 50 min. The reaction was terminated at
85°C for 5 min. One microliter of RNase H was added, and the reaction
was incubated for 20 min at 37°C. The resulting cDNA was stored at
20°C and used in the real-time PCR step. The primer pairs used for
APP, Sp1, -site APP cleaving enzyme 1 (BACE1), and GAPDH were as
follows: Sp1, sense, 5-CAA GCC CAA ACA ATC ACC TT-3, and anti-
sense, 5-CAA TGGGTGTGAGAGTGGTG-3; BACE1, sense, 5-TTT
GTG GAG ATG GTG GAC AA-3, and antisense, 5-CAG CAC CCA
CTG CAA AGT TA-3; APP, sense, 5-GCT GGC TGA ACC CCA GAT-
3, and antisense, 5-CCC ACT TCC CAT TCT GGA CAT-3; GAPDH,
sense, 5-TGA AGC AGG CGT CGG AGG G-3, and antisense, 5-CGA
AGG TGG AAG AGT GGG TG-3. Each real-time PCRmix contained 1
l of cDNA, 1 l of primer mix (final concentration, 200 nM), 10.5 l of
nuclease-free water, and 12.5 l of SYBR GREEN PCRMaster Mix (Ap-
plied Biosystems, Foster City, CA). Each sample had triplicates. Real-
time PCRwas conducted for all of the above genes with respective primer
pairs in a 7500 Real-Time PCR System following standard protocol, that
was, 50°C for 2 min followed by 95°C for 10 min, and then 40 cycles of
95°C for 15 s and 60°C for 1 min. Real-time PCR products were checked
with agarose gel to confirm that no nonspecific products formed. Results
were analyzed with 7500 system software with relative quantification
method using GAPDH as endogenous control. Other housekeeping
genes such as -actin were also used.
A1–40 and A1–42 assay. The levels of A were measured using
human A (1–40 and 1–42) assay kits (Immuno-Biological Laborato-
ries, Gunma, Japan). These kits were designed as solid-phase sandwich
ELISA with two kinds of highly specific antibodies. The assay conditions
were followed according to the method described by Morishima-
Kawashima et al. (2000), with slight modifications. Brain tissue was ho-
mogenized in Tris-saline (TS) [50 mM Tris-HCl buffer, pH 7.4, 150 mM
NaCl, 1 g/ml TLCK (N--p-tosyl-L-lysine chloromethyl ketone), 1
g/ml antipain, 0.5 mM DIFP (diisopropyl fluorophosphates), 0.5 mM
PMSF, 0.1% protease inhibitor mixture] and centrifuged at 100,000 g
for 20 min at 4°C. The pellet was resuspended in 4 vol of TS and centri-
fuged at 70,000 g for 20 min at 4°C. The resultant pellet was dissolved
in 500l of 6 M guanidine-HCl (in 50mMTris buffer, pH 7.6), incubated
at room temperature for 30min, and centrifuged at 70,000 g for 20min
at 4°C. The resultant supernatant was collected and diluted by enzyme
immunoassay (EIA) buffer (supplied with the kit) to 12 to reduce
sample guanidine-HCl concentration, and aliquots (200g of protein in
100 l of EIA buffer) and assay standards were added to a 96-well plate
[precoated with anti-human A (35–40) (1A10)Mouse IgGMoAb] and
incubated overnight at 4°C. The wells were washed seven times with EIA
buffer. Then, 100 l of labeled antibody was added to each well contain-
ing sample or standard and incubated at 4°C for 1 h. The wells were
washed nine times with EIA buffer followed by the addition of 100 l of
TMB buffer, and incubated in the dark for 30 min at room temperature.
The reaction was stopped by adding 100 l of 1N H2SO4, and the color-
imetric absorption was performed at 450 nm. The levels of A in the test
samples were calculated relative to the standard curve generated on each
plate.
Immunohistochemistry. The cellular distribution of APP, SP1, and A
was examined in paraffin-embedded brain tissue of control (Con) and
developmentally, Pb-exposed (Pb-E), 23-year-old cynomolgus mon-
keys. The sections were subjected to brief washes in 1 PBS and 3%
hydrogen peroxide. After rinsing, the sections were incubated in PBS
containing 2% BSA and 1% Triton X-100 blocking solution for 30 min,
and then incubated in the presence of primary antibody for APP (22C11;
1:200; Sigma, St. Louis, MO), A (6E10; 1:50; Sigma), or SP1 (SC-59;
1:100; Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4°C.
Sections were washed with PBS and incubated along with the species-
specific biotinylated secondary antibody mouse/rabbit (1:200; Vector
Laboratories, Burlingame, CA) for 30 min. The sections were incubated
with streptavidin (Vector Laboratories) for 30 min, rinsed briefly with
PBS, and immunoreactivity was detected with the substrate DAB (3–3-
diaminobenzidine-tetrahydrochloride) (Vector Laboratories). Cover-
slips were mounted with Permanent Mounting Medium (Vector
Laboratories).
In all cases, negative controls were run on slides from each animal by
omitting the primary antibody incubation. No signal was evident after
incubation of tissues in secondary antibody alone.
Nuclear protein extraction. Nuclear proteins were extracted from the
frontal association cortical tissue of control and Pb-exposed animals
according to the method described by Dignam et al. (1983), with slight
modifications. Tissue samples were homogenized with 1 ml of PBS, pH
7.4, and centrifuged at 2500  g for 10 min at room temperature. The
pellets obtainedwere suspended in 5 vol of buffer A (10mMHEPES at pH
7.9, 1.5 mMMgCl2, 0.5 mM DTT, 0.5 mM EDTA, and 0.2 mM PMSF) and
centrifuged at 6000 g for 2min at 4°C. The pellets were resuspended in
3 vol of buffer A and centrifuged at 6000  g for 2 min at 4°C. The
resulting pellets were then resuspended in 5 vol of buffer C (20 mM
HEPES at pH 7.9, 1.5 mM MgCl2, 0.5 mM DTT, 0.5 mM EDTA, 420 mM
NaCl, 20% glycerol, 0.2 mM PMSF, 0.002 mg/ml aprotinin, and 0.0005
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mg/ml leupeptin) and homogenized. The final suspensions were centri-
fuged at 12,000 g for 10 min. The supernatants were transferred to 1.5
ml tubes, snap frozen in an ethanol dry-ice bath, and stored at 80°C
(Basha et al., 2005).
Primary mice cortical neuronal cell culture. Because the animals we
studied were 23 years of age and we did not have early time points to
measure the progression of the molecular or epigenetic changes, we used
a cell culture model to address some of the mechanistic questions. We
used the C57BL/6 mouse as a source of primary fetal cortical neurons
based on the wide use of this genetic background strain for various trans-
genic mice AD models. The C57BL/6 mice (Charles River Laboratories,
Wilmington, MA) fetuses were used to generate primary cortical neuro-
nal cultures. Animal usage was approved (Approval AN00-01-007) and
monitored by the Institutional Animal Care and Use Committee of the
University of Rhode Island. Brains were excised, and cortices were dis-
sected from day 15 mouse pups from the same dam. Meninges were
removed and cortical tissue was incubated for 15 min at 37°C in 5 ml of
HBSS containing papain (2mg/ml). Tissuewas centrifuged at 125 g for
5 min, and the resulting pellet was resuspended in HBSS and cells were
dissociated with trituration through a fire-polished Pasteur pipette and
repeated three times. After centrifugation, cells were plated at a constant
density of 6.5 104/well, in 24-well poly-D-lysine-precoated plates. The
plating medium contained 2% B27, 0.5 mM [SCAP]L-glutamine, and 25
M glutamic acid inNeurobasalmedium (Invitrogen) andmaintained at
37°C in a humidified atmosphere of 5% CO2. After 4 d in culture, one-
half of the medium was replaced with fresh medium devoid of glutamic
acid and the cultures were maintained. To determine methyltransferase
activity, cells in the 24-well plates were treated with 0.1M Pb at the time
of medium change for 24 h. Pb was removed and cells were aged for 7 d
before nuclear extract was harvested and subjected to methyltransferase
activity assay.
8-oxo-dGdetermination. 8-oxo-dG levelswere determined byHPLCas
described previously (Bolin et al., 2006). Briefly, sample tissue was ho-
mogenized in nuclease-free homogenization buffer followedby digestion
with proteinase K to remove proteins. The DNA was precipitated by
three consecutive organic extractions, precipitation by 2 vol of ethanol
(with respect to the aqueous volume), and incubated overnight at
20°C. The purified DNA was prepared for HPLC analysis by nuclease
digestion into deoxynucleoside components. The amount of 8-oxo-dG
and 2-deoxyguanosine (2-dG) was calculated by comparing the peak
areas of 8-oxo-dG and 2-dGobtained from the enzymatic hydrolysate of
the DNA sample to a calibration curve for both compounds. Levels of
8-oxo-dG in the samples were expressed relative to the content of 2-dG
[e.g., the molar ratio of 8-oxo-dG/2-dG (femtomoles of 8-oxo-dG per
nanomole of 2-dG)]. TheHPLCmethod used for analysis of the samples
was as follows: themobile phase consisted of 100mM sodium acetate, pH
5.2, with 5% methanol. Flow rate was kept at 1 ml/min using a Model 582
SolventDeliveryModule (ESA, Chelmsford,MA).DNAwas analyzed using
a reverse-phase YMC basic HPLC column (4.6  150 mm) with a 3 m
particle size (YMC, Wilmington, NC). 8-oxo-dG and 2-dG were detected
by a Model 5600A CoulArray Detector (ESA) with three model 6210 four-
channel electrochemical cells; potentials were set at 175, 200, and 250 V for
8-oxo-dG and at 785, 850, and 890V for 2-dG.Data were recorded, stored,
and analyzed with CoulArray for Windows32 Software (ESA). Data were
expressed as femtomoles of 8-oxo-dG per nanomole of 2-dG.
DNA methyltransferase assay. DNAmethyltransferase activity was de-
termined in nuclear extracts derived from the control and Pb-exposed
frontal associated cortical tissue. Nuclear extracts were derived as de-
scribed above, and the DNA methyltransferase activity was assayed fol-
lowing themethod described by Takiguchi et al. (2003). Nuclear extracts
containing 60 g of protein (source of methyltransferase) were incu-
bated with 50 ng of deoxyinosine-deoxycytidine (poly[dI.dC].poly-
[dI.dC]) double-stranded DNA template (Sigma) as a substrate, 1 M
3H-labeled S-adenosyl methionine (SAM) (79 Ci/mmol), 100 mM Tris-
HCl, pH 8.2, in a final volume of 30 l. The reaction was initiated by the
addition of SAM for 1 h at 37°C and terminated by chilling on ice. A 15l
aliquot was spotted on DE81 filter paper and washed with sodium phos-
phate buffer, pH 7.0, twice, once with 70% ethanol, and once with 100%
ethanol. The filter was dried and counted in a scintillation counter.
Statistical treatment. Data were analyzed using two-tailed Student’s t
test, and the values marked with an asterisk were significantly different
from the control group ( p 0.05).
Results
Pb levels
The exposure of these primate animals to low levels of inor-
ganic Pb from birth to 400 d resulted in blood Pb levels of
19–26 g/dl when being dosed with Pb after weaning from
infant formula. This level is slightly above the 10 g/dl con-
sidered safe for humans by the Centers for Disease Control
and Prevention (1991) and is similar to the exposure scenario
we previously used in lifetime studies with rats (Basha et al.,
2005). Sampling during young adulthood demonstrated clear-
ance of Pb from the blood and levels were similar for both
control and Pb-exposed monkeys (Rice, 1992). Thus, any signif-
icant exposure was limited to the developing and adolescent period.
In the aged animals, Pb levels in brain tissue were analyzed using
Elemental Analyzer ICP-MS, and we found that Pb levels for both
exposed and control animals remained below the detection levels
(0.1 ng/g wet weight of tissue).
Latent expression of APP, A, BACE1, and Sp1
The amino acid sequence of APP of cynomolgus monkeys is ho-
mologous (96%) to that of humans, making it a good model for
studies of the pathological effects of A in the primate brain
(Podlisny et al., 1991). The enzyme BACE1 plays a major role in
the cleavage of APP (Singer et al., 2005), and transcription factor
Sp1 (Lahiri and Robakis, 1991; Christensen et al., 2004) is a
known regulator of both genes. Therefore, we compared APP,
BACE1, and Sp1 mRNA levels in the control and developmen-
tally Pb-exposed aged primates. The mRNA levels of all three
genes (Fig. 1) were elevated in primates exposed to Pb as infants;
however, the elevation in BACE1 was not statistically significant
( p 0.063). Quantification of results indicated that APPmRNA
levels increased 50% ( p 0.045); A1–40 levels increased 50%
( p 0.011); and A1–42 levels increased 100% ( p 0.029), in
a manner similar to that previously seen in rodents (Fig. 2A,B).
Whereas rodents have non-plaque-forming A with 3 aa differ-
ent from that of primates, APP of cynomolgus monkey shares
96% sequence homology with human, and both species have
same plaque-forming A peptides, which is more clinically rele-
vant. Furthermore, the ratio of A1–42 to A1–40 increased as a
result of developmental exposure to Pb (Fig. 2B). Exposure of
cultured mouse primary neurons to these peptides confirmed
that both of these peptides were toxic to the cells even in the
soluble form and that A1–42 was more cytotoxic than A1–40
(supplemental Fig. 1, available at www.jneurosci.org as supple-
mental material).
Alteration of AD pathology
Immunohistochemical analysis of the frontal association cortex
was undertaken to determine whether the observed molecular
changes in APP expression and A levels were accompanied by
changes in the pathological features of the brains of these animals.
The brains of the aged monkeys developmentally exposed to Pb
revealed an increase in the intracellular staining of total A and
dense-core plaques compared with age-matched controls (Fig.
3). Highermagnification of intracellular A staining revealed the
accumulation of immunoreactive A aggregates inside neuronal
cells, the budding of some of these A species from the mem-
brane as well as their deposition in the extracellular space (Fig. 3).
We also observed diffuse and cored plaques and NFTs morpho-
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logically similar to those observed in human brain. The A
plaques were found to be rich in A1–42, the more amyloido-
genic species of A, and were detectable using Congo red
staining.
DNA methylation
The latent expression of genes observed in these animals may be
mediated through epigenetic pathways that are regulated via
DNA methylation. To determine whether developmental expo-
sure to Pb interfered with DNA-methylation patterns, we exam-
ined the activity of DNA methyltransferase 1 (DNMT1) in the
23-year-old primate brain tissues. The activity of thismethylating
enzyme is selective for cytosine in a CpG dinucleotide, which is
base-paired to a methylated CpG sequence on the complemen-
tary strand of DNA and is directly proportional to the abundance
of methyl groups on CpG dinucleotides in the DNA (Poirier and
Vlasova, 2002; Takiguchi et al., 2003). We found the activity of
DNMT1 to be reduced by 20% in brain tissue derived from
developmentally Pb-exposed primates (Fig. 4B). Exposure of
mouse primary cells from the cortex to low levels of Pb (0.1 M)
for a transient 24 h period followed by aging of the cells for 1week
produced a similar trend in DNMT1 activity (Fig. 4A).
DNA oxidation
In addition to the alteration in APP and A deposition, age-
related accumulation of oxidative damage is suspected to play a
role in the pathogenesis of AD.A levels arewell known to induce
functional disturbance in vivo through their pro-oxidant and
neurotoxic properties (Castellani et al., 2006). Along with the
increase seen in A levels in the cortex of developmentally Pb-
exposed animals, higher levels of the biomarker of oxidativeDNA
damage, 8-oxo-dG were noted (Fig. 5).
Discussion
Thedatapresented in thispaper showthatmonkeys exposed toPbat
birth to 400 d upregulate the expression of APP, BACE1, and Sp1 in
old age. The upregulation of both APP and BACE1 gene expression
Figure 1. Changes in mRNA expression of APP, BACE1, and Sp1 in the frontal association
cortex of aged monkeys after developmental exposure to Pb. The frontal association cortical
tissue of 23-year-old control (Con) and Pb-exposed (Pb-E) monkeys were analyzed for mRNA
expression of APP, BACE1, and Sp1. The mRNA expression of APP, BACE1, and Sp1 were vali-
dated by real-time PCR. Data shown represent the mean SEM (4 animals in each group).
Values marked with an asterisk are significantly different from their corresponding controls
( p 0.05) as determined by Student’s t test.
Figure2. ElevationofA levels in the frontalassociationcortexof23-year-oldcynomolgusmon-
keysafterdevelopmentalexposuretoPb.Braintissueofcontrol(Con)andPb-exposed(Pb-E)23-year-
old cynomolgusmonkeys was used for the analysis of A levels (A,B). The levels of Aweremea-
sured in the frontal associationcortical tissueusingELISAasdescribed inMaterials andMethods.Data
shownrepresent themeanSEMfor fouranimals ineachgroup.Valuesmarkedwithanasteriskare
significantlydifferentfromtheircorrespondingcontrols ( p0.05)asdeterminedbyStudent’s t test.
Figure 3. Photomicrographs showing AD-like pathology in the frontal association cortex of
23-year-old cynomolgus monkeys after developmental exposure to Pb. Brain tissue of control
(Con) and Pb-exposed (Pb-E) 23-year-old cynomolgus monkeys was used for the analysis of
immunohistochemical analysis of AD-like pathology. Sections were prepared and stained with
the A-specific antibody, which recognizes both A1–40 and A1–42 as discussed in Mate-
rials andMethods. The arrows point to A-containing plaques as well as granular and intracel-
lular staining. The staining characteristics are similar to those reported in the literature.
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ismediated by Sp1, and the essentiality of Sp1 as amediator of these
delayed transcriptional upregulations has been previously shown by
us (Basha et al., 2005). Moreover, both APP and BACE1 gene pro-
moters are rich in CpG dinucleotides and GC box elements (Poll-
wein et al., 1992), making them subjected to epigenetic reprogram-
ming and transcriptional regulation viaDNAmethylation pathways
(Lahiri et al., 2007). This is further reinforced by preliminary mi-
croarray screens, which showed that95% of the differentially ex-
pressed genes screened in control versus Pb-exposed monkeys
were also CpG-rich (supplemental Table 1, available at www.
jneurosci.org as supplementalmaterial). This transcriptional repro-
gramming at the gene level is also translated into biological conse-
quences. Levels of amyloidogenic products of APP were also in-
creased in the aged animals that were exposed to Pb as infants (Fig.
2A).This is consistentwithprevious findings in rodents (Bashaet al.,
2005) and argues for a transcriptional process that promotes neuro-
degeneration in old age (Lahiri et al., 2007).
Notably, these molecular and biochemical changes observed in
23-year-old animals are accompanied by altered features of AD-like
pathology in the exposedmonkeys.Our intracellular staining closely
resembleswhat is seen inhumans andother animalmodels (Mochi-
zuki et al., 1996; Schmitz et al., 2004). It reveals granular, oval, and
crescent-shaped A localization in pyramidal cells and globular-
shapedneurons in layers II–IVof the cortex.Theoccurrenceof these
molecular, biochemical, and pathological changes in primates that
developplaques and tangles inold age, in response todevelopmental
exposure to Pb, suggests that developmental exposure can influence
latentpathogenesis, hencebearing adirect relevance tohumans.The
possibility that developmental exposure to Pb could result in the
formation of ADpathology in humans is further supported by find-
ings in a patient who survived from severe Pb toxicity at 2 years of
age, but diedof severemental deterioration at the age of 42 (Niklow-
itz and Mandybur, 1975). The brain of this patient revealed many
senile plaques and NFTs (Niklowitz and Mandybur, 1975). Al-
though this is a single case, the plausibility that early exposure to Pb
could be a risk factor for ADwarrants additional study.
One way to achieve permanent changes or long-term alteration
in gene expression is to alter the structuralmakeupof theDNAbases
that determine the sequence-specific DNA-binding of a transcrip-
tion factor. Our findings with changed DNA methyltransferase ac-
tivity argue that exposure to Pb early in life interferes with gene
imprinting and could thus leave a permanentmolecular damage on
theDNA.That is to say, expressionhasbeenreprogrammedthrough
imposition of a pathogenic somatic epitype (Lahiri and Maloney,
2007). Consistent with such a potential mechanism is the decreased
activityof theDNAmethylatingenzyme in theagedanimals exposed
to Pb as infants, as well as the delayed decrease in the activity of this
enzyme in cells that had previous exposure to Pb (Fig. 4).
This is further supported by studies that show that regions of
the human APP promoter upstream of500 bp displayed tissue
and brain region-specific profiles of methylation, which approx-
imately reflect APP expression patterns (Rogaev et al., 1994) and
age-related reduction in methylcytosine (224 to 101) that
occur on the human APP promoter (Tohgi et al., 1999). To link
the association of an epigenetic phenomenon in current model,
we hypothesize that genes that are regulated by methylation can
be reprogrammed in adulthood as a result of infantile exposure to
inorganic Pb. This hypothesis was supported by our microarray
screening of 588 neurobiology-related genes.We found thatmost
of the genes (20 of 22) that were altered because of infantile
exposure to Pb were rich (60%) in CpG dinucleotides (supple-
mental Table 1, available at www.jneurosci.org as supplemental
material). However, our own work herein and previously (Basha
et al., 2005) has shown that, although SP1 and APP are upregu-
lated in a latent manner after early exposure to Pb in both cyno-
molgus monkeys and rats, other genes regulated by SP1, such as
BACE1 (Christensen et al., 2004), do not respond in rodents
(Bolin et al., 2006) and show a modest trend in primates.
In addition, SP1 regulates a wide variety of other genes that have
not been shown to respond in this latent manner to early Pb expo-
sure. This does not exclude SP1 from an active role in latent Pb-
induced pathogenesis. Although the APP and BACE1 promoters
from humans and primates contain sites for SP1 binding (Song and
Lahiri, 1998; Sambamurti et al., 2004), the specific position of these
sites differwith regard to their respective transcription start sites. For
example, active SP1 sites in the APP gene appear in its 5-
untranslated region(UTR)(Villa et al., 2004),whereas theactiveSP1
site in the BACE1 promoter is1 kb upstream of the transcription
start (Christensen et al., 2004). Alternatively, general density of CpG
dinucleotides in combination with presence of transcription factor
sites (such as SP1) may explain the differential effects between APP
and BACE1. Comparison of the cumulative potential methyl CpG
dinucleotides 2 kb upstreamof the transcription start sites indicated
Figure 4. DNA methyltransferase activity in cortical neuronal cells of mice and in monkey
brains. A, B, Control and Pb-exposed mouse cortical neuronal cells (A) and frontal association
cortical tissue of 23-year-old control (Con) and Pb-exposed (Pb-E) monkeys (B) were used to
estimate the DNA methyltransferase activity as described in Materials and Methods. Data
shown represent the mean SEM for four independent determinations (4 animals in each
group for monkey data). Values marked with an asterisk are significantly different from their
corresponding controls ( p 0.05) as determined by Student’s t test.
Figure 5. Oxidative DNA damage in control and infantile-exposed aged monkey brains.
Frontal association cortical tissues were obtained from 23-year-old control (Con) and Pb-
exposed (Pb-E) monkeys and used to measure the marker of oxidative DNA damage as de-
scribed in Materials and Methods. Data shown represent the mean SEM for four animals in
each group. Valuesmarkedwith an asterisk are significantly different from their corresponding
controls ( p 0.05) as determined by Student’s t test.
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that the proximal promoter regions surveyed by
Bolinet al. (2006) suggestedadifference inmeth-
ylation site density centered around100.
Ample evidence has accumulated that oxida-
tive damage to macromolecules such as DNA,
protein, and lipids (Cecchi et al., 2002; Esposito
et al., 2006), as well as a downregulation in anti-
oxidant enzymes are associated with AD (Smith
and Perry, 1995). We previously found eleva-
tions in the oxidative DNAmarker 8-oxo-dG in
older rats that had been developmentally ex-
posed toPb(Bolinet al., 2006).Here,wealso find
asimilaraccumulationof8-oxo-dG(Fig.5).This
latent accumulationof oxidizedDNAcouldpos-
sibly come from two sources. The latent increase
in A could promote the formation of reactive
oxygen species, thus damaging the DNA; and/or
epigenetic modulation in the methylation pat-
ternof cytosines could interferewith the repairof
oxidized guanines or render themmore suscep-
tible to oxidative damage (Evans and Cooke,
2004).
Few studies address both DNA methylation
andDNAoxidativedamageas anepigeneticphe-
nomenon. Researchers using synthetic DNAoli-
gonucleotides with bothmethylation and oxida-
tivedamage ina singleCpGsiteoroxidizeddGat
a complementary strandhave foundoxidationof
guanine in a CpG dinucleotide reduced the
methyl group binding domain (MBD) binding
to that site (Valinluck et al., 2004). Even the oxi-
dation on the guanine in the opposite strand diminished the MBD
binding but not so much as the same strand G-oxidation. When
5-methylcytosine was oxidized to 5-hydroxymethylcytosine, its af-
finity to MBD is greatly reduced to the same level as unmethylated
cytosine. We thus hypothesize that epigenetic mechanisms such as
DNAmethylation can influence oxidative damage andmake organ-
isms more susceptible to the pathogenesis of AD and that this pro-
cess can bemodulated by environmental exposure.
We, therefore, propose amodel (Fig. 6) of interaction between
methylation and oxidative damage in genes reprogramming. Us-
ing the APP gene proximal promoter/5-UTR sequence as an
example, in undamaged genes, methyl CpG binding protein 2
(MECP2) would compete against transcription factors such as
SP1 for regulation. The resulting competition would downregu-
late a given gene. If target DNA is altered via oxidation to
8-oxo-dG or 5-hydroxymethylcytosine, MECP2 binding may be
partially or completely blocked, but insufficiently to permit suf-
ficient competing SP1 interaction with the sequence to change
expression (Fig. 6B). Normal changes of development, maturity,
and aging result in triggering of latent SP1 regulatory alterations,
which significantly increase levels of the transcription factor (Fig.
6C). The greater levels of SP1, when combinedwith partial block-
age ofMECP2 binding, permit sufficient SP1 interaction with the
sequence to result in greater target gene expression. It is likely that
other transcription factors may function as competitive targets
for MECP2 in addition to SP1.
Adult diseases such as schizophrenia have also been linked to
infection, fetal malnutrition, or hypoxia in early life (Dalman et al.,
1999; Van Erp et al., 2002; Boksa and El-Khodor, 2003). A study by
Bilbo et al. (2005) showed that perinatal exposure to an infectious
agent affected how the nervous system responded to an immune
challenge and memory consolidation later in adulthood. The au-
thors also found that neonatal pathogen exposure decreased the
number of adult hippocampal astrocytes, increased their reactivity,
and decreased brain IL-1 levels after adult lipopolysaccharide ex-
posure. Work in autism spectrum disorders has demonstrated at
least some contribution of differential methylation (Jiang et al.,
2004). In this context, recent results showing increased plasma-
soluble APP levels in patients of “autism with aggression” may
provide an epigenetic role for APP in autism spectrum disorders, as
per environmentally mediated LEARn regulation (Sokol et al.,
2006). Hypomethylation of theDRD2 andHTR2A genes have been
implicated in both schizophrenia and bipolar disorder (Abdol-
maleky et al., 2004). However, hypermethylation of the RELN gene
has been shown to associatewith schizophrenia (Abdolmaleky et al.,
2005), indicating that latent pathogenic effects of epigenetic pertur-
bations may work on more than one mechanism. Although our
work specifically addressed latent effects of Pb, othermetalsmayhave a
similar effect (Poirier andVlasova, 2002; Takiguchi et al., 2003).
In conclusion, this study presents novel findings in primates
that implicate an environmental agent (Pb) in the pathogenesis of
AD and demonstrate that development is an important period of
vulnerability, which could increase future susceptibility to neu-
rodegeneration and AD pathology.
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